

Multiple endocrine neoplasia, type 1

Inherited predisposition to multifocal endocrine neoplasia

Pathology • Molecular mechanisms • Morphology • Clinical correlations

Dr Abu Suraih Sakhri


MBBS, MD (Pathology)

www.abusuraihsakhri.com

Learning objectives

- Recognize the characteristic MEN1 organ distribution and its clinical consequences.
- Explain how a germline MEN1 defect predisposes to multiple endocrine lesions.
- Relate parathyroid, gastroenteropancreatic and pituitary lesions to their hormone syndromes.
- Discriminate MEN1 from sporadic endocrine tumors and selected MEN phenocopies.

MEN syndromes are systemic tumor predispositions



Hyperplasia, adenomas, and carcinomas may coexist across the syndrome spectrum.

Inherited endocrine tumors differ from sporadic tumors

Feature	MEN-associated pattern	Sporadic pattern
Age	Often earlier onset	More often later presentation
Distribution	More than one organ possible	Usually one organ
Focality	Multifocal within an organ	Often solitary
Chronology	Synchronous or metachronous	Usually isolated event

MEN1 is Wermer syndrome

- A rare inherited syndrome of endocrine proliferative lesions.
- Textbook prevalence: Approximately 2 per 100,000.
- The defining distribution is parathyroid, enteropancreatic endocrine tissue, and anterior pituitary.
- Clinical illness reflects both hormone secretion and neoplastic behavior.

The three Ps organize the MEN1 phenotype

Parathyroid

Primary
hyperparathyroidism

Pancreas / duodenum

Neuroendocrine
neoplasms

Pituitary

Prolactinoma; Other
PitNETs


“Pancreatic” includes clinically important duodenal gastrinomas.

MEN1 expression varies among organ systems

Organ group	Dominant abnormality	Major clinical signal
Parathyroid	Adenomas and/or hyperplasia	PTH-related hypercalcemia
Duodenum / pancreas	Often multifocal neuroendocrine neoplasms	Peptic ulcers or hypoglycemia
Anterior pituitary	Often lactotroph tumor	Prolactin-excess manifestations

Multifocality is more informative than tumor size

One dominant lesion



Dominant focus


Multiple microscopic lesions



Scattered small foci


A clinically evident endocrine tumor may coexist with additional small lesions in the same organ.

Synchronous and metachronous disease




An apparently isolated initial lesion does not exclude a hereditary syndrome.

Hormone excess and tumor burden are different axes



MEN1 encodes the tumor-suppressor-associated protein menin



Menin participates in several transcription factor complexes.

Menin acts in context-dependent transcriptional complexes


Molecular fact

- MEN1 encodes menin.
- Menin associates with multiple transcription factor complexes.

Biological implication

- Its effect depends on interacting partners.
- Menin can promote or restrain tumorigenesis according to cellular context.

Germline susceptibility is not the same as a visible tumor



Conceptual tumor-suppressor model; No patient-specific mutation sequence implied.

MEN1 mutations also occur in sporadic neoplasms

Hereditary MEN1 syndrome

- Germline MEN1 defect.
- Multi-organ tumor predisposition.
- May show multiple lesions.


Sporadic endocrine neoplasm

- MEN1 changes can arise somatically.
- The genetic event may remain confined to one tumor.
- A mutation in a tumor alone does not establish inherited MEN1.

An organ-specific mutation does not establish MEN1

- Sporadic parathyroid adenomas can harbor somatic MEN1 changes.
- Some sporadic pancreatic neuroendocrine neoplasms also have MEN1 mutations.
- Interpret family history, tumor distribution and germline status separately.
- Do not equate tumor sequencing with germline predisposition.

Family-based interpretation requires organ-level synthesis



Framework for reasoning; No unverified surveillance interval or test threshold is prescribed.

Parathyroid disease dominates MEN1 presentation

- Primary hyperparathyroidism is the most common MEN1 manifestation.
- Involvement in approximately 80%–95% of patients.
- It is the first recognized manifestation in most affected individuals.
- Near-universal appearance by about age 40–50 years.

MEN1 parathyroid lesions include hyperplasia and adenomas


Hyperplasia

- Expansion of parathyroid cellular mass.
- Can involve several glands.
- Autonomous PTH secretion may develop.

Adenoma

- Discrete endocrine neoplasm.
- May coexist with other proliferative lesions.
- The MEN1 context alters expectations about focality.

Autonomous PTH secretion produces primary hyperparathyroidism



Mechanistic compression of textbook parathyroid physiology and disease.


PTH has coordinated skeletal and renal actions

Target	Relevant action of PTH	Manifestation when excessive
Bone	Promotes osteoclastic bone resorption indirectly	Skeletal mineral loss
Kidney	Promotes calcium conservation	Contributes to higher serum calcium
Calcium balance	Raises circulating free calcium	Hypercalcemia and urinary stone risk

Hypercalcemia may be clinically silent

- Primary hyperparathyroidism is often first detected on routine chemistry testing.
- Symptoms are not required for clinically significant endocrine disease.
- A hypercalcemic patient needs an etiologic evaluation—not an assumption of MEN1.
- Family history and additional endocrine lesions increase suspicion for a syndrome.

PTH excess links MEN1 to nephrolithiasis



Nephrolithiasis is an explicitly described MEN1-related clinical presentation.

Sustained hyperparathyroidism can damage bone

- PTH-associated bone resorption can lower skeletal mass.
- Severe untreated disease may cause osteitis fibrosa cystica.
- Brown tumors are reactive lesions following bone injury and hemorrhage.
- These skeletal consequences are not themselves primary bone malignancies.

Parathyroid morphology must be interpreted in context

Observation	What it indicates	What it cannot establish alone
Increased chief-cell density	Parathyroid proliferative lesion	Germline MEN1 status
Reduced stromal fat	May accompany hyperplasia/adenoma	Single vs multiple affected glands
Multiple enlarged glands	Suggests a multigland process	Specific syndrome without clinical context

Sporadic solitary adenoma is the key comparator

Sporadic primary hyperparathyroidism

- A solitary adenoma is the commonest cause.
- Usually presents without additional syndromic endocrine tumors.

MEN1-associated hyperparathyroidism

- Hyperplasia and adenomas occur.
- Multigland involvement and other endocrine lesions strengthen suspicion.

Parathyroid disease can obscure other MEN1 lesions

A younger adult presents with recurrent renal calculi, raised serum calcium and non-suppressed PTH.


What should the endocrine-pathology assessment not overlook?

The possibility of a syndromic cause if multifocal parathyroid disease, family history or another endocrine lesion is identified.

Enteropancreatic neuroendocrine disease drives major risk

- Gastroenteropancreatic endocrine tumors are a major source of MEN1 morbidity and mortality.
- Clinically aggressive behavior in some MEN1 tumors.
- Multiple microscopic lesions may coexist with one or two dominant masses.
- Both hormonal syndromes and metastatic disease matter.

Pancreatic multifocality is a characteristic pattern



Small microadenomas can be distributed throughout the organ with one or more dominant lesions.


PanNEN is the contemporary pathologic umbrella term

- Pancreatic neuroendocrine neoplasms (PanNENs) arise from endocrine-lineage cells.
- They may be functioning or clinically nonfunctioning.
- Histologic differentiation and proliferation inform tumor classification.
- MEN1-associated lesions must be interpreted within a hereditary, frequently multifocal setting.

Differentiation, grade and hormone function are distinct

Domain	Key question	Not equivalent to
Differentiation	What neoplastic phenotype is present?	Whether hormone symptoms occur
Proliferation	How actively is the tumor growing?	Tumor anatomical multiplicity
Function	Is there a hormone-driven syndrome?	Guaranteed indolent behavior

Not every secretory tumor creates a clinical syndrome




Pancreatic polypeptide is often secreted in MEN1 but frequently has no overt hypersecretion syndrome.

Pancreatic polypeptide illustrates “functional” ambiguity


- MEN1-associated pancreatic endocrine neoplasms may elaborate pancreatic polypeptide.
- Pancreatic polypeptide is often the predominant secretory product account.
- A detectable secretory product need not yield a specific clinical hormone-excess syndrome.
- Clinical functioning should be described separately from immunohistochemical expression.

Gastrinoma frequently arises in the duodenum



In MEN1 the duodenum is more often the site of gastrinomas than the pancreas; Both may occur together.

Gastrin excess causes Zollinger–Ellison syndrome




Pathophysiologic clinical correlation grounded in pancreatic chapter and MEN1 discussion.

Ulcer severity is an endocrine diagnostic clue

- Gastrinoma-associated acid excess can cause intractable peptic ulcers.
- Repeated or unusually severe ulcer disease invites consideration of a gastrin-secreting tumor.
- In MEN1, duodenal location is particularly important.
- A presumed pancreatic-only tumor search can miss clinically relevant lesions.

Synchronous duodenal and pancreatic tumors are possible

Duodenal gastrinoma



Dominant focus


Pancreatic endocrine lesions



Scattered small foci

One MEN1 patient can harbor lesions at both sites; A single mass does not explain the entire risk.

Insulinoma produces endogenous hyperinsulinism



Insulinoma is not established by hypoglycemia in isolation.

Hypoglycemia explains insulinoma neurologic symptoms

- Central nervous system function depends on glucose availability.
- Severe low glucose may produce confusion, stupor or loss of consciousness.
- Episodes often relate to fasting or exertion description.
- Improvement after glucose is a clinical clue, not a stand-alone tumor diagnosis.

Endogenous insulin secretion requires biochemical correlation

Finding during hypoglycemia	Diagnostic implication
Insulin not appropriately suppressed	Supports inappropriate insulin secretion
Elevated C-peptide	Supports endogenous rather than injected insulin
Clinical symptom pattern	Defines urgency and guides contextual evaluation
Alternative causes excluded	Avoids misclassifying nonneoplastic hypoglycemia

An insulinoma differential prevents false attribution

- Adrenal insufficiency and advanced liver disease may cause hypoglycemia.
- Drug-related hypoglycemia, including sulfonylureas, is an important alternative.
- Exogenous insulin administration requires separate consideration.
- MEN1 status does not remove the need for biochemical confirmation.

Morphology alone cannot reliably determine PanNEN behavior

Microscopic appearance

- May appear monotonous and well differentiated.
- A low-power bland appearance can be deceptive.

Behavioral assessment

- Consider mitotic activity / Ki-67 in appropriate contexts.
- Evaluate extent, invasion and metastasis.
- Integrate disease site and clinical course.

The dominant mass is not the whole pancreatic disease

In an MEN1 carrier, imaging demonstrates one sizable pancreatic lesion; Additional small lesions are described in the resection.

How should the specimen and clinical imaging be conceptualized?

As potentially multifocal endocrine neoplasia, with individual lesions requiring morphologic and clinical characterization.


The three endocrine presentations demand different tests

Syndrome	Dominant clinical problem	Biochemical concept
Hyperparathyroidism	Hypercalcemia / stones	Serum calcium with PTH context
Gastrinoma	Acid hypersecretion / ulceration	Inappropriately increased gastrin
Insulinoma	Hypoglycemia / neuroglycopenia	Insulin and C-peptide during hypoglycemia

Pituitary tumors complete the MEN1 triad

- The anterior pituitary is the third major endocrine site in MEN1.
- The most frequently encountered pituitary lesion is a prolactinoma.
- Somatotropin-secreting tumors may produce acromegaly.
- Clinical findings may reflect hormonal secretion or local mass effect.

Prolactinoma causes an endocrine syndrome



Clinical phenotype depends on sex, age and reproductive context.


Prolactin excess is not specific to prolactinoma

Alternative source of hyperprolactinemia	Interpretive implication
Pregnancy / lactation	Physiologic elevation
Pituitary stalk interference	Loss of hypothalamic dopamine inhibition
Dopamine-antagonist drugs	Pharmacologic disinhibition
Renal failure / hypothyroidism	Systemic causes of raised prolactin

A pituitary mass may manifest by mass effect

- Expanding lesions can extend beyond the sella.
- Compression of the optic apparatus may disturb visual fields.
- Larger tumors may impair normal pituitary function.
- Hormone secretion and lesion size should be assessed as separate issues.

Somatotroph tumors cause GH-related tissue growth



The clinical syndrome depends on developmental timing.

Acromegaly translates biochemistry into morphology

- After epiphyseal closure, GH/IGF-1 excess enlarges acral soft tissues and bone.
- Characteristic changes include broadening hands, feet and facial structures.
- The syndrome may evolve insidiously before tumor diagnosis.
- The MEN1 clinical context is relevant when acromegaly accompanies other endocrine disease.

Pituitary morphology requires lineage integration

Assessment axis	Pathology contribution
Architecture	Monomorphic cell population with altered reticulin network
Hormone expression	PRL and GH can support relevant functional subtypes
Cell lineage	Lineage-associated transcription factors aid classification
Clinical state	Hormone phenotype and mass effects remain indispensable

A pituitary tumor need not be the presenting lesion

A person treated for primary hyperparathyroidism later develops galactorrhea and biochemical prolactin excess.

What unifying interpretation should be considered?

Multiple endocrine neoplasia type 1, while excluding other causes of hyperprolactinemia and confirming the pituitary lesion.


MEN1 extends beyond the three Ps

Additional site / finding	Textbook relationship
Duodenum	Common gastrinoma site
Other neuroendocrine (carcinoid) tumors	Increased occurrence
Thyroid / adrenal cortex	Adenomas occur more frequently
Soft tissue	Lipomas more frequent than population background

Additional lesions are clues, not defining substitutes


- A lipoma or thyroid adenoma is common and nonspecific in isolation.
- The significance rises when it accompanies a characteristic endocrine triad lesion.
- Multisite interpretation is more informative than any single incidental lesion.
- Avoid overdiagnosing MEN1 based on one low-specificity finding.

The endocrine phenotype can change over time



Illustrative possible sequence; Not an individual-level prediction.

MEN1 can cause both morbidity and mortality



Clinical priorities differ among MEN1 lesions

Compartment	Primary injury mechanism	Core clinical priority
Parathyroid	Chronic PTH excess	Calcium and renal / skeletal effects
Gastrinoma	Excess gastric acid	Ulcer complications
Insulinoma	Endogenous hypoglycemia	Neuroglycopenic risk
PanNEN with aggressive behavior	Tumor invasion / spread	Extent and progression
Pituitary	Hormone excess / mass effect	Endocrine + neuro-ophthalmic assessment

MEN1 and MEN2 are distinct genetic syndromes

Feature	MEN1	MEN2A (contrast)
Gene	MEN1 tumor suppressor	RET proto-oncogene
Typical endocrine sites	Parathyroid, duodenum/pancreas, pituitary	Medullary thyroid carcinoma, pheochromocytoma ± parathyroid
Principal mechanism	Altered menin function	Activating RET signaling
Most useful discriminator	Enteropancreatic/pituitary pattern	Medullary thyroid carcinoma + adrenal chromaffin tumor

MEN1-like disease can have another genetic basis

MEN1

- Germline MEN1 alteration.
- Menin-related tumor susceptibility.
- Classic three-P distribution.

MEN1 phenocopy / MEN4 context

- CDKN1B changes can create a MEN1-like clinical picture.
- Gene-based distinction matters.
- Clinical overlap is not molecular identity.

Parathyroid carcinoma suggests an alternate syndrome

- Classic MEN1 parathyroid disease includes adenomas and hyperplasia.
- An invasive parathyroid carcinoma warrants consideration of distinct genetic predispositions.
- The textbook associates CDC73 defects with hyperparathyroidism–jaw tumor syndrome.
- Do not assign every familial parathyroid tumor to MEN1.

Distinguish multiple tumors from one multihormonal tumor


MEN1 multisite neoplasia

- Independent lesions may occur in different endocrine organs.
- Several hormonal syndromes may coexist.

Multihormonal PanNEN

- One tumor may produce several hormones.
- Multiple hormone assays do not prove multiple neoplasms.

Suspected MEN1: Reasoning from phenotype to genotype



Conceptual evaluation flow; No surveillance or germline testing thresholds asserted.

Case: Ulcer disease and biochemical hyperparathyroidism

A patient with recurrent severe peptic ulceration also has PTH-dependent hypercalcemia. Imaging shows a small duodenal endocrine mass.

Which combination most strongly favors a syndromic hypothesis?

Coexisting primary hyperparathyroidism and a gastrinoma-pattern lesion strongly suggest the MEN1 phenotype.

Case: Normal-looking cells, consequential disease

A pancreatic neuroendocrine lesion shows relatively uniform cells, but imaging detects additional foci and a distant deposit.

Which inference would be unsafe?

That bland cytology guarantees biologic indolence. Multifocality and metastatic status must be assessed independently.

Case: A single MEN1 feature is not diagnostic

An older adult has a solitary parathyroid adenoma without relevant family history, pancreatic lesions or pituitary manifestations.

Which conclusion is most defensible?

A sporadic adenoma is plausible. One parathyroid lesion alone does not establish inherited MEN1.

MEN1: Clinicopathologic synthesis

Genetic substrate

Germline MEN1; Altered
menin

Tissue phenotype

Multisite, often multifocal
tumors

Clinical outcome

Hormonal syndromes ±
malignant spread

Think in parallel: Genotype, morphology, and hormone physiology.

Five findings that should remain linked

- The three Ps: Parathyroid, enteropancreatic system and pituitary.
- Primary hyperparathyroidism is common and usually the initial manifestation.
- Duodenal gastrinomas and multifocal pancreatic lesions are important.
- Prolactinoma is the characteristic pituitary lesion; Somatotroph tumors also occur.
- Germline MEN1–menin dysfunction underlies a multisite neoplastic predisposition.

Principal textbook references

- Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026). The Endocrine System.
- Relevant sections: Multiple Endocrine Neoplasia Syndromes; Multiple Endocrine Neoplasia, Type 1.
- Relevant sections: Primary Hyperparathyroidism; Pancreatic Neuroendocrine Neoplasms.
- Relevant sections: Lactotroph PitNET; Somatotroph PitNET.